These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28431775)

  • 1. Cinacalcet Hydrochloride.
    Mostafa GAE; Al-Badr AA
    Profiles Drug Subst Excip Relat Methodol; 2017; 42():1-90. PubMed ID: 28431775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir.
    Al-Badr AA; Ajarim TDS
    Profiles Drug Subst Excip Relat Methodol; 2018; 43():1-208. PubMed ID: 29678260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic.
    Ohya Y; Osaki M; Sakai S; Kimura S; Yasuda C; Ago T; Kitazono T; Arakawa S
    BMC Neurol; 2018 May; 18(1):62. PubMed ID: 29734949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
    PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacarbazine.
    Al-Badr AA; Alodhaib MM
    Profiles Drug Subst Excip Relat Methodol; 2016; 41():323-77. PubMed ID: 26940170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefdinir.
    Al-Badr AA; Alasseiri FA
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():41-112. PubMed ID: 24794905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation.
    Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione.
    Alanazi AM; Mostafa GA; Al-Badr AA
    Profiles Drug Subst Excip Relat Methodol; 2015; 40():43-158. PubMed ID: 26051685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin sodium.
    Al-Badr AA; Mostafa GA
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():433-513. PubMed ID: 24794911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
    Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
    Nemeth EF; Shoback D
    Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
    Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discussion.
    Surgery; 2016 Jan; 159(1):191-2. PubMed ID: 26476827
    [No Abstract]   [Full Text] [Related]  

  • 18. [The use of Cinacalcet in chronic kidney disease: a case report].
    Russo R; Argentino G; Maresca ID; Sannino G; Memoli A; Memoli B
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.